KBY Biotech Indexv0.0.34
Search
← Pipeline|Elracapivasertib

Elracapivasertib

NDA/BLA
PRO-9417
By Proteon (Charles River)
Source: Trial-derived·Trials: 1
Modality
Bispecific Ab
MOA
RAS(ON)i
Target
PARP
Pathway
PI3K/AKT
ALL
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
~Aug 2021
→ ~Nov 2022
Phase 3
~Feb 2023
→ ~May 2024
NDA/BLA
Aug 2024
→ Jun 2025
NDA/BLACurrent
NCT06926145
928 pts·ALL
2024-08→2025-06·Not yet recruiting
928 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0810mo agoPh3 Readout· ALL
Trial Timeline
Q42025Q2
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2025-06-08 · 10mo ago
ALL
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT06926145NDA/BLAALLNot yet recr...928EDSS
Competitors (10)
DrugCompanyPhaseTargetMOA
MiriosocimabPfizerPhase 1PARPALKi
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
NVO-2974Novo NordiskNDA/BLAPARPMenini
SemainavolisibGilead SciencesPhase 2PARPPRMT5i
REG-861RegeneronPhase 2PARPAuroraAi
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
180-3597Innovent BioPreclinicalSHP2RAS(ON)i